The positive Phase 3 HAELO data and BLA trajectory are the dominant catalysts — monitor FDA acceptance in H2 2026 and potential launch in H1 2027. The financial miss is secondary for a pre-revenue biotech. Watch for HLA genotyping findings in nex-z trials and MAGNITUDE-2 enrollment completion.
Price Chart
Executive Summary
Intellia Therapeutics reported Q2 2026 results with a net loss of $106.6M (-$0.80 EPS, -2.6% miss vs consensus) and collaboration revenue of $7.7M (-46% YoY, 41% miss). The primary stock-moving event is the positive Phase 3 HAELO data for lonvo-z in HAE, published in NEJM, with BLA submission expected in H2 2026 and U.S. launch in H1 2027. The company ended Q2 with $628M cash, funding operations into 2028.
Key Financial Metrics
Key Facts
- Phase 3 HAELO trial met primary endpoint: 87% attack reduction vs placebo (p<0.0001)
- 62% of lonvo-z patients attack-free and therapy-free for 6 months vs 11% placebo
- BLA submission for lonvo-z expected in H2 2026; potential U.S. launch in H1 2027
- Enrollment resumed in nex-z Phase 3 MAGNITUDE trials; MAGNITUDE-2 completion expected H2 2026
- Cash, cash equivalents and marketable securities: $628.4M as of June 30, 2026
- Net loss per share: -$0.80 vs consensus -$0.78 (miss)
- Collaboration revenue: $7.7M vs $13.0M consensus (miss) and $14.2M in Q2 2025
Financial Impact
Earnings missed by 2.6% on EPS and 40.8% on revenue; collaboration revenue declined 46% YoY
Risk Factors
- BLA acceptance or FDA review timeline could be delayed
- Nex-z safety signal (liver transaminase elevations) may impact regulatory discussions
- Cash burn rate of ~$106M/quarter may require additional financing before lonvo-z launch
- Competition from other HAE treatments (Takhzyro, Orladeyo, etc.)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-336772 |
| Document: ntla-20260806.htm | 0001193125-26-336772 |
| Document: 0001193125-26-336772-index-headers.html | 0001193125-26-336772 |
| Document: 0001193125-26-336772-index.html | 0001193125-26-336772 |
| Document: 0001193125-26-336772.txt | 0001193125-26-336772 |
| 8-K Data (Synthetic) | 0001193125-26-336772 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 23d ago | Press Release | $12.75 $12.58 | ▼ −1.33% | ▼ −1.76% | $11.23 (−11.92%) |
Sep 8, 2026 6w ago | 8-K | $12.21 $11.60 | ▼ −5.00% | ▼ −4.66% | $11.23 (−8.03%) |
Aug 6, 2026 11w ago | 8-K | $11.24 $11.83 | ▲ +5.25% | ▲ +4.04% | $11.23 (−0.09%) |
Jun 15, 2026 19w ago | 8-K | $14.92 $15.75 | ▲ +5.56% | ▲ +6.95% | $11.23 (−24.73%) |
Jun 13, 2026 19w ago | Press Release | $14.92 $15.75 | ▲ +5.56% | ▲ +6.95% | $11.23 (−24.73%) |
Jun 1, 2026 21w ago | Press Release | $13.73 $13.54 | ▼ −1.38% | ▲ +1.37% | $11.23 (−18.21%) |
May 11, 2026 24w ago | 8-K | $14.42 $12.69 | ▼ −12.00% | ▼ −11.91% | $11.23 (−22.12%) |
Apr 27, 2026 25w ago | Press Release | $13.20 $13.87 | ▼ −5.08% | ▼ −3.38% | $11.23 (+14.92%) |
Apr 27, 2026 26w ago | 8-K | $13.04 $13.87 | ▲ +6.37% | ▲ +5.96% | $11.23 (−13.88%) |
Apr 3, 2026 29w ago | Press Release | $13.30 $14.26 | ▲ +7.22% | ▲ +3.08% | $11.23 (−15.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers